Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × Vemurafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 24 Neoplasm Metastasis 7 Neoplasms 6 Lymphoma, Non-Hodgkin 4 Leukemia, Hairy Cell 4 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Thyroid Neoplasms 2 Thyroid Cancer, Papillary 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Multiple Myeloma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Glioma 2 Ependymoma 2 Central Nervous System Neoplasms 2 Xanthogranuloma, Juvenile 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Skin Neoplasms 1 Sarcoma, Clear Cell 1 Relapsed Pediatric Solid Tumor 1 Rare Tumour 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡